Literature DB >> 35928099

Antimullerian Hormone Levels and Association with Abortion and Preterm Delivery in Patients with Polycystic Ovary Syndrome Who Conceived with Assisted Reproductive Techniques.

Walid A Abdelsalam1, Ola A Harb2, Sherin A Shazly1.   

Abstract

Background: Pregnant PCOS patients were found to suffer from many adverse outcomes of pregnancy. Prediction of the fate of pregnancy and labor in PCOS patients was highly needed. There were recently discovered roles of serum AMH in those patients who were seeking for pregnancy and who were conceiving with assisted reproductive techniques. Aim: To analyze the predictive roles of measuring serum levels of AMH in patients with PCOS who became pregnant spontaneously or used assisted reproductive techniques regarding abortion and preterm delivery. Patients and Study Design: A total of 100 females with PCOS were included in the study and they underwent assisted reproductive techniques were included in the study and underwent measurement of AMH levels regularly.
Results: We found that a total of 70 patients had a term delivery, and 30 patients had a preterm delivery. We found no statistically significant differences between both groups regarding their age or body mass index (BMI). We showed that serum AMH levels were higher in the group of PCOS patients who had preterm delivery than in the group of patients with term delivery (p < .0.001). Conclusions: High serum AMH levels were found to be associated with higher risks of occurrence of preterm labor in patients with PCOS who underwent assisted reproductive techniques. Our results gave a clue to clinicians for better management of the pregnancy process in these patients. © Federation of Obstetric & Gynecological Societies of India 2022.

Entities:  

Keywords:  Antimullerian hormone; Assisted reproductive techniques; Polycystic ovary syndrome; Preterm delivery

Year:  2022        PMID: 35928099      PMCID: PMC9343493          DOI: 10.1007/s13224-021-01506-w

Source DB:  PubMed          Journal:  J Obstet Gynaecol India        ISSN: 0975-6434


  17 in total

1.  Double measurements of serum HCG concentration and its ratio may predict IVF outcome.

Authors:  Hongbin Chi; Jie Qiao; Hongzhen Li; Ping Liu; Caihong Ma
Journal:  Reprod Biomed Online       Date:  2010-01-11       Impact factor: 3.828

2.  Müllerian-Inhibiting Substance/Anti-Müllerian Hormone as a Predictor of Preterm Birth in Polycystic Ovary Syndrome.

Authors:  Jennifer Y Hsu; Kaitlyn E James; Charles L Bormann; Patricia K Donahoe; David Pépin; Mary E Sabatini
Journal:  J Clin Endocrinol Metab       Date:  2018-11-01       Impact factor: 5.958

Review 3.  Interactions between androgens, FSH, anti-Müllerian hormone and estradiol during folliculogenesis in the human normal and polycystic ovary.

Authors:  Didier Dewailly; Geoffroy Robin; Maëliss Peigne; Christine Decanter; Pascal Pigny; Sophie Catteau-Jonard
Journal:  Hum Reprod Update       Date:  2016-08-27       Impact factor: 15.610

4.  Use of the serum anti-Müllerian hormone assay as a surrogate for polycystic ovarian morphology: impact on diagnosis and phenotypic classification of polycystic ovary syndrome.

Authors:  Alice Fraissinet; Geoffroy Robin; Pascal Pigny; Tiphaine Lefebvre; Sophie Catteau-Jonard; Didier Dewailly
Journal:  Hum Reprod       Date:  2017-08-01       Impact factor: 6.918

5.  Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome.

Authors: 
Journal:  Fertil Steril       Date:  2004-01       Impact factor: 7.329

6.  Characterization of women with elevated antimüllerian hormone levels (AMH): correlation of AMH with polycystic ovarian syndrome phenotypes and assisted reproductive technology outcomes.

Authors:  Reshef Tal; David B Seifer; Moisey Khanimov; Henry E Malter; Richard V Grazi; Ben Leader
Journal:  Am J Obstet Gynecol       Date:  2014-03-02       Impact factor: 8.661

7.  Isolation of the bovine and human genes for Müllerian inhibiting substance and expression of the human gene in animal cells.

Authors:  R L Cate; R J Mattaliano; C Hession; R Tizard; N M Farber; A Cheung; E G Ninfa; A Z Frey; D J Gash; E P Chow
Journal:  Cell       Date:  1986-06-06       Impact factor: 41.582

Review 8.  The physiology and clinical utility of anti-Mullerian hormone in women.

Authors:  Didier Dewailly; Claus Yding Andersen; Adam Balen; Frank Broekmans; Nafi Dilaver; Renato Fanchin; Georg Griesinger; Tom W Kelsey; Antonio La Marca; Cornelius Lambalk; Helen Mason; Scott M Nelson; Jenny A Visser; W Hamish Wallace; Richard A Anderson
Journal:  Hum Reprod Update       Date:  2014-01-14       Impact factor: 15.610

9.  Elevated prenatal anti-Müllerian hormone reprograms the fetus and induces polycystic ovary syndrome in adulthood.

Authors:  Brooke Tata; Nour El Houda Mimouni; Anne-Laure Barbotin; Samuel A Malone; Anne Loyens; Pascal Pigny; Didier Dewailly; Sophie Catteau-Jonard; Inger Sundström-Poromaa; Terhi T Piltonen; Federica Dal Bello; Claudio Medana; Vincent Prevot; Jerome Clasadonte; Paolo Giacobini
Journal:  Nat Med       Date:  2018-05-14       Impact factor: 53.440

Review 10.  Epidemiology and causes of preterm birth.

Authors:  Robert L Goldenberg; Jennifer F Culhane; Jay D Iams; Roberto Romero
Journal:  Lancet       Date:  2008-01-05       Impact factor: 79.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.